Dipeptidyl Peptidase-4 Inhibitor-induced Autoimmune Diseases: Current Evidence

Overview

Journal World J Diabetes

Publisher Baishideng Publishing Group

Specialty Endocrinology

Date 2021 Oct 11

PMID 34630898

Citations 6

Authors

Ayan Roy

Jayaprakash Sahoo

Niya Narayanan

Chandhana Merugu

Sadishkumar Kamalanathan

Dukhabandhu Naik

Affiliations

Soon will be listed here.

Abstract

Dipeptidyl peptidase-4 inhibitors (DPP-4i) have an important place in the management of type 2 diabetes. The DPP-4 enzyme is ubiquitously distributed throughout the human body and has multiple substrates through which it regulates several important physiological functions. DPP-4 regulates several immune functions, including T-cell activation, macrophage function, and secretion of cytokines. Studies have reported an increase in autoimmune diseases like bullous pemphigoid, inflammatory bowel disease, and arthritis with DPP-4i use. The relationship of DPP-4i and autoimmune diseases is a complex one and warrants further research into the effect of DPP-4 inhibition on the immune system to understand the pathogenesis more clearly. Whether a particular cluster of autoimmune diseases is associated with DPP-4i use remains an important contentious issue. Nevertheless, a heightened awareness from the clinicians is required to identify and treat any such diseases. Through this review, we explore the clinical and pathophysiological characteristics of this association in light of recent evidence.

Citing Articles

Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases.

Uslu N, Gungor K, Tamer G, Can B Medeni Med J. 2024; 39(2):140-143.

PMID: 38940531 PMC: 11572276. DOI: 10.4274/MMJ.galenos.2024.76508.

Bullous Pemphigoid Associated With Dipeptidyl Peptidase-4 Inhibitors: A Case Report and Review of Current Evidence.

Hadjkacem F, Frikha H, Boujelben K, Chaari C, Mnif E, Masmoudi A Hosp Pharm. 2023; 58(4):357-362.

PMID: 37360199 PMC: 10288458. DOI: 10.1177/00185787231151861.

Glucose as a Potential Key to Fuel Inflammation in Rheumatoid Arthritis.

Masuko K Nutrients. 2022; 14(11).

PMID: 35684149 PMC: 9182926. DOI: 10.3390/nu14112349.

Low levels of soluble DPP4 among Saudis may have constituted a risk factor for MERS endemicity.

Alkharsah K, Aljaroodi S, Rahman J, Alnafie A, Al Dossary R, Aljindan R PLoS One. 2022; 17(4):e0266603.

PMID: 35413090 PMC: 9004781. DOI: 10.1371/journal.pone.0266603.

Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.

Huang J, Liu X, Wei Y, Li X, Gao S, Dong L Front Immunol. 2022; 13:830863.

PMID: 35309368 PMC: 8931313. DOI: 10.3389/fimmu.2022.830863.

References

Lee S, Lee H, Yoon M, Kim D . Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes. JAMA Dermatol. 2019; 155(2):172-177. PMC: 6439542. DOI: 10.1001/jamadermatol.2018.4556. View

Bellinato F, Maurelli M, Schena D, Gisondi P, Girolomoni G . Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Ital J Dermatol Venerol. 2020; 156(4):455-459. DOI: 10.23736/S2784-8671.20.06562-1. View

Phan K, Charlton O, Smith S . Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Australas J Dermatol. 2019; 61(1):e15-e21. DOI: 10.1111/ajd.13100. View

Pantea Stoian A, Sachinidis A, Stoica R, Nikolic D, Patti A, Rizvi A . The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020; 109:154295. DOI: 10.1016/j.metabol.2020.154295. View

Kridin K, Bergman R . Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol. 2018; 154(10):1152-1158. PMC: 6233738. DOI: 10.1001/jamadermatol.2018.2352. View

Garcia-Diez I, Ivars-Lleo M, Lopez-Aventin D, Ishii N, Hashimoto T, Iranzo P . Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization. Int J Dermatol. 2018; 57(7):810-816. DOI: 10.1111/ijd.14005. View

Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H . HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J Invest Dermatol. 2017; 138(5):1201-1204. DOI: 10.1016/j.jid.2017.11.023. View

Sayiner Z, Okyar B, Kisacik B, Akarsu E, Ozkaya M, Araz M . DPP-4 INHIBITORS INCREASE THE INCIDENCE OF ARTHRITIS/ARTHRALGIA BUT DO NOT AFFECT AUTOIMMUNITY. Acta Endocrinol (Buchar). 2019; 14(4):473-476. PMC: 6516418. DOI: 10.4183/aeb.2018.473. View

Yokota K, Igaki N . Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Intern Med. 2012; 51(15):2041-4. DOI: 10.2169/internalmedicine.51.7592. View

10.

Zhuge F, Ni Y, Nagashimada M, Nagata N, Xu L, Mukaida N . DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization. Diabetes. 2016; 65(10):2966-79. DOI: 10.2337/db16-0317. View

11.

Aso Y, Kase M, Sagara M, Sakurai S, Iijima T, Tomaru T . Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes. Am J Med Sci. 2020; 360(3):261-267. DOI: 10.1016/j.amjms.2020.05.005. View

12.

Silverii G, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M . Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine. 2020; 69(3):504-507. DOI: 10.1007/s12020-020-02272-x. View

13.

Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas I . Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2011; 26(2):249-53. DOI: 10.1111/j.1468-3083.2011.04062.x. View

14.

Schaffer C, Buclin T, Jornayvaz F, Cazzaniga S, Borradori L, Gilliet M . Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. Dermatology. 2017; 233(5):401-403. DOI: 10.1159/000480498. View

15.

Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A . Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig. 2018; 10(2):392-398. PMC: 6400158. DOI: 10.1111/jdi.12877. View

16.

Reolid A, Munoz-Aceituno E, Rodriguez-Jimenez P, Gonzalez-Rojano E, Llamas-Velasco M, Fraga J . Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database. Int J Dermatol. 2019; 59(2):197-206. DOI: 10.1111/ijd.14658. View

17.

Melo F, Pinto-Lopes P, Estevinho M, Magro F . The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2020; 27(7):1153-1165. DOI: 10.1093/ibd/izaa324. View

18.

Douros A, Rouette J, Yin H, Yu O, Filion K, Azoulay L . Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. Diabetes Care. 2019; 42(8):1496-1503. DOI: 10.2337/dc19-0409. View

19.

Zheng W, Zhou J, Song S, Kong W, Xia W, Chen L . Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice. Int J Endocrinol. 2018; 2018:8309723. PMC: 6079465. DOI: 10.1155/2018/8309723. View

20.

Okauchi Y, Tomoda Y, Takata M, Deguchi A, Takata M, Takenoshita Y . Pemphigus vulgaris developing after 6-month treatment with a dipeptidyl peptidase-4 inhibitor: A case report. J Dermatol. 2017; 45(2):e39-e40. DOI: 10.1111/1346-8138.14076. View